Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Medicure has completed the enrollment of 3,000 patients for its Phase III trial for its drug for patients undergoing heart surgery ahead of schedule.
Subscribe to our email newsletter
The double-blind, randomized, placebo-controlled clinical trial – MEND-CABG II – will evaluate the safety and cardioprotective efficacy of its product, MC-1, in patients undergoing coronary artery bypass graft surgery (CABG).
Albert Friesen, president and CEO, said: “The completion of patient enrollment in MEND-CABG II, which is two months ahead of schedule, is a testament to the support and confidence of the clinical investigators and patients participating in the trial. We believe MC-1 represents an important advancement in the care of coronary artery bypass graft surgery patients, and could become the first cardioprotective therapy approved to reduce mortality and morbidity in this patient population. We therefore look forward to reporting top-line results from MEND-CABG II early next year.”